NCT05891275Completed
Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
Characterization of Patients With Geographic Atrophy (GA) in the US
Source: ClinicalTrials.gov · Last updated 1 May 2025
Brief summary (registry, in English)
To quantify and describe patients with a Geographic Atrophy (GA) diagnosis in at least one eye, and the progression to neovascular Age-Related Macular Degeneration (including how many receive Anti-VEGF), or to GA (in the fellow eye only).
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 68563 (actual)
- First submitted
- 26 May 2023
- Start date
- 31 May 2023
- Primary completion date
- 1 Dec 2023
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Macular degeneration
- NCT number
- NCT05891275
What you commit to
- Study type: Observational
- Participants enrolled: 68563
- From 31 May 2023 to the primary completion date, 1 Dec 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \- Patients without the information of laterality will be excluded.
Who the study is looking for
- \- All patients ≥50 years, with a GA diagnosis in at least one eye, included in the Vestrum database identified during the study period (January 2015 to April 2023).
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CorEvitas HQ Coordinator of this site? Confirm its status | Waltham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.